The goal is to help ensure that prescription drug marketing information for consumers and healthcare providers is truthful and balanced. Here’s what the agency plans to research.
Experts weigh in on a recent lawsuit against PBMs, whether similar lawsuits will crop up, and the likely outcomes.
About half of states have transitioned at least some Medicaid beneficiaries away from fee-for-service (FFS) drug programs into drug plans integrated with managed care. Our policy analyst shares why he believes more should do so.
Switzerland-based pharma company Roche’s $1.9 billion purchase of tech company Flatiron Health signifies Big Pharma’s need for data.
A Pacific Research Institute report revealed that the 340B program is in desperate need of reform, while 340B Health refutes damaging claims.
This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.
Shocking opioid overdose statistics make it crucial to address the epidemic. Here are four programs to watch
Overprescribing by just one practitioner can lead to an untoward outcome that may readily affect the entire healthcare facility.
Insiders unmask what policy actions will continue and what will develop in the next year.
A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.